HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells
Agents that inhibit histone deacetylases (HDAC inhibitors) have been shown to enhance radiation response. The aim of this study was to evaluate the effects of low, minimally cytotoxic concentrations of the HDAC inhibitor, valproic acid (VPA), on radiation response of colorectal cancer cells. Cell li...
Saved in:
Published in: | Cancer biotherapy & radiopharmaceuticals Vol. 24; no. 6; p. 689 |
---|---|
Main Authors: | , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
01-12-2009
|
Subjects: | |
Online Access: | Get more information |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Agents that inhibit histone deacetylases (HDAC inhibitors) have been shown to enhance radiation response. The aim of this study was to evaluate the effects of low, minimally cytotoxic concentrations of the HDAC inhibitor, valproic acid (VPA), on radiation response of colorectal cancer cells. Cell lines LS174T and an isogenic pair of HCT116, which differed only for the presence of wild-type p53, were exposed to ionizing radiation (IR) alone, VPA alone, or the combination. Clonogenic survival, gamma-H2AX induction, apoptosis, changes in mitochondrial membrane potential, and mitochondrial levels of p53 and Bcl-2 family proteins were assessed. In vivo studies monitored tumor growth suppression after therapy in mice bearing HCT116/p53(+/+) and HCT116/p53(-/-) tumor xenografts. VPA led to radiosensitization, which was dependent on p53 status. A decrease in clonogenic survival, an increase in apoptosis, and an increase in levels of gamma-H2AX were observed after VPA+IR, compared to IR alone, in wild-type p53 cells (LS174T and HCT116/p53(+/+)), as opposed to p53 null cells (HCT116/p53(-/-)). Exposure to VPA resulted in enhancement of IR-induced mitochondrial localizations of Bax and Bcl-xL, mitochondrial membrane potential, and cytochrome c release only in wild-type p53 cell lines. VPA also enhanced tumor growth suppression after IR only in wild-type p53 xenografts. These data suggest that VPA may have an important role in enhancing radiotherapy response in colorectal cancer, particularly in tumors with the wild-type p53 genotype. |
---|---|
AbstractList | Agents that inhibit histone deacetylases (HDAC inhibitors) have been shown to enhance radiation response. The aim of this study was to evaluate the effects of low, minimally cytotoxic concentrations of the HDAC inhibitor, valproic acid (VPA), on radiation response of colorectal cancer cells. Cell lines LS174T and an isogenic pair of HCT116, which differed only for the presence of wild-type p53, were exposed to ionizing radiation (IR) alone, VPA alone, or the combination. Clonogenic survival, gamma-H2AX induction, apoptosis, changes in mitochondrial membrane potential, and mitochondrial levels of p53 and Bcl-2 family proteins were assessed. In vivo studies monitored tumor growth suppression after therapy in mice bearing HCT116/p53(+/+) and HCT116/p53(-/-) tumor xenografts. VPA led to radiosensitization, which was dependent on p53 status. A decrease in clonogenic survival, an increase in apoptosis, and an increase in levels of gamma-H2AX were observed after VPA+IR, compared to IR alone, in wild-type p53 cells (LS174T and HCT116/p53(+/+)), as opposed to p53 null cells (HCT116/p53(-/-)). Exposure to VPA resulted in enhancement of IR-induced mitochondrial localizations of Bax and Bcl-xL, mitochondrial membrane potential, and cytochrome c release only in wild-type p53 cell lines. VPA also enhanced tumor growth suppression after IR only in wild-type p53 xenografts. These data suggest that VPA may have an important role in enhancing radiotherapy response in colorectal cancer, particularly in tumors with the wild-type p53 genotype. |
Author | Chen, Xufeng Wong, Jeffrey Y C Radany, Eric Wong, Patty |
Author_xml | – sequence: 1 givenname: Xufeng surname: Chen fullname: Chen, Xufeng organization: Department of Radiation Oncology, City of Hope Cancer Center, Duarte, California 91010, USA – sequence: 2 givenname: Patty surname: Wong fullname: Wong, Patty – sequence: 3 givenname: Eric surname: Radany fullname: Radany, Eric – sequence: 4 givenname: Jeffrey Y C surname: Wong fullname: Wong, Jeffrey Y C |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20025549$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j0tLAzEYRYMo9qFLt5If0Bm_ySSTZFnGaoWCG11KyRMj02RIpoL-egvq6l44lwN3gc5jig6hmwbqBoS8MzrXBEDW0BF5huYNY7wSgpEZWpTyAQAddPwSzU4jwhiVc_S2vV_3OMT3oMOU8gp_qmHMKRisTLCrE7FH4woeWVtZN7poXZxwVjak4mIJU_hWU0gRJ49NGk7FqGhcxsYNQ7lCF14NxV3_5RK9Pmxe-m21e3586te7ylDRTpVvlBKCK-c1NUKD5bKVgjoLVoAgsjOeatp0ynHfcqEF9bazXADjsjFUkSW6_fWOR31wdj_mcFD5a___k_wAJJNVMw |
CitedBy_id | crossref_primary_10_1016_j_ajme_2017_04_002 crossref_primary_10_3892_ol_2013_1245 crossref_primary_10_3892_ol_2017_5792 crossref_primary_10_1186_s13048_016_0267_2 crossref_primary_10_3389_fonc_2021_722754 crossref_primary_10_1111_j_1582_4934_2011_01296_x crossref_primary_10_1517_13543784_2012_694425 crossref_primary_10_1007_s00438_010_0550_7 crossref_primary_10_1016_j_freeradbiomed_2014_05_019 crossref_primary_10_1007_s10637_018_0696_4 crossref_primary_10_1089_omi_2010_0026 crossref_primary_10_18632_oncotarget_10790 crossref_primary_10_3892_or_2015_4089 crossref_primary_10_1259_bjr_20140649 crossref_primary_10_1016_j_canlet_2014_09_049 crossref_primary_10_1186_1748_717X_9_89 crossref_primary_10_1007_s11060_011_0725_z crossref_primary_10_3109_02688697_2011_638996 crossref_primary_10_1007_s00432_011_1093_y crossref_primary_10_1155_2017_6326053 crossref_primary_10_18632_oncotarget_5253 crossref_primary_10_4103_abr_abr_91_19 crossref_primary_10_1002_cbin_11591 crossref_primary_10_17795_jjnpp_22818 crossref_primary_10_2217_fon_2020_0385 crossref_primary_10_1371_journal_pone_0016795 crossref_primary_10_1016_j_procbio_2014_07_022 crossref_primary_10_3892_or_2015_3879 crossref_primary_10_1155_2013_374593 crossref_primary_10_1038_bjc_2013_21 crossref_primary_10_1186_s13148_021_01025_5 crossref_primary_10_1039_C5TX00476D crossref_primary_10_1017_erm_2024_15 crossref_primary_10_1021_acs_jmedchem_0c00491 crossref_primary_10_1517_13543784_2013_853037 crossref_primary_10_1038_s41598_021_92466_8 crossref_primary_10_1093_jrr_rrt227 crossref_primary_10_3892_ol_2013_1666 crossref_primary_10_1038_bjc_2016_278 crossref_primary_10_1109_TCBB_2020_3019781 crossref_primary_10_1186_s13046_017_0647_5 crossref_primary_10_1007_s11060_013_1129_z crossref_primary_10_3389_fonc_2021_646256 crossref_primary_10_1038_s41598_017_15165_3 crossref_primary_10_3390_radiation2010011 crossref_primary_10_1007_s11033_014_3246_y crossref_primary_10_1016_j_radonc_2015_10_009 crossref_primary_10_1016_j_tranon_2016_12_011 crossref_primary_10_2217_fon_10_53 crossref_primary_10_1186_s12935_016_0306_5 crossref_primary_10_18632_oncotarget_3692 crossref_primary_10_1007_s11060_012_0978_1 crossref_primary_10_1155_2011_514261 crossref_primary_10_1002_adtp_202300421 crossref_primary_10_1007_s10495_014_1042_8 crossref_primary_10_1186_1752_0509_9_S5_S4 crossref_primary_10_1038_s41598_019_40054_2 crossref_primary_10_1007_s11523_015_0370_0 crossref_primary_10_1080_07391102_2017_1302820 crossref_primary_10_1089_omi_2010_0053 crossref_primary_10_3390_cancers13194905 crossref_primary_10_1177_2050640618792819 crossref_primary_10_4143_crt_2014_026 crossref_primary_10_1186_s12967_021_03171_z |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1089/cbr.2009.0629 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1557-8852 |
ExternalDocumentID | 20025549 |
Genre | Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: CA 33572 |
GroupedDBID | --- .GJ 0R~ 1-M 29B 34G 39C 3V. 4.4 53G 5GY 5RE 6PF 7X7 88A 88E 88I 8C1 8FE 8FH 8FI 8FJ 8WZ A6W AAWTL ABBKN ABJNI ABUWG ACGFS ACGOD ACPRK ADBBV AENEX AFKRA AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AZQEC BBNVY BENPR BHPHI BNQNF BPHCQ BVXVI CAG CCPQU CGR COF CS3 CUY CVF DU5 DWQXO EBS ECM EIF EJD F5P FYUFA GNUQQ HCIFZ HMCUK IAO IHR IM4 INH INR ITC L7B LK8 M0L M1P M2P M7P NPM O9- P2P PQQKQ PROAC PSQYO RIG RML RMSOB UDS UE5 UKHRP ZGI |
ID | FETCH-LOGICAL-c483t-f1aa887aefb4c8b0d793984ed0d808296cf4b416ae7f378b84fd6d7805791c4a2 |
IngestDate | Sat Sep 28 07:46:34 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c483t-f1aa887aefb4c8b0d793984ed0d808296cf4b416ae7f378b84fd6d7805791c4a2 |
OpenAccessLink | https://europepmc.org/articles/pmc2920759?pdf=render |
PMID | 20025549 |
ParticipantIDs | pubmed_primary_20025549 |
PublicationCentury | 2000 |
PublicationDate | 2009-Dec |
PublicationDateYYYYMMDD | 2009-12-01 |
PublicationDate_xml | – month: 12 year: 2009 text: 2009-Dec |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Cancer biotherapy & radiopharmaceuticals |
PublicationTitleAlternate | Cancer Biother Radiopharm |
PublicationYear | 2009 |
References | 17464244 - Cancer J. 2007 Jan-Feb;13(1):30-9 16830229 - Apoptosis. 2006 Aug;11(8):1349-57 9488723 - J Biol Chem. 1998 Mar 6;273(10):5858-68 15746940 - Cell Death Differ. 2005 May;12(5):482-91 14729640 - Cancer Res. 2004 Jan 1;64(1):316-21 12667443 - Mol Cell. 2003 Mar;11(3):577-90 15179185 - Melanoma Res. 2004 Jun;14(3):173-81 7624142 - Oncogene. 1995 Jul 20;11(2):253-61 10101800 - Semin Cancer Biol. 1998;8(5):345-57 9581811 - Cancer Res. 1998 May 1;58(9):1779-84 15077143 - Oncogene. 2004 Apr 12;23(16):2797-808 15050820 - J Mol Biol. 2004 Apr 16;338(1):17-31 15496622 - N Engl J Med. 2004 Oct 21;351(17):1731-40 6739728 - Radiat Res. 1984 Jul;99(1):73-84 11861406 - Cancer Res. 2002 Feb 15;62(4):1213-21 7930835 - Int J Radiat Biol. 1994 Oct;66(4):329-41 11790986 - Curr Opin Oncol. 2002 Jan;14(1):86-91 15867370 - Cancer Res. 2005 May 1;65(9):3745-50 12667439 - Mol Cell. 2003 Mar;11(3):552-4 9135890 - Clin Oncol (R Coll Radiol). 1997;9(2):70-8 15549093 - Nature. 2004 Nov 18;432(7015):316-23 7983426 - Int J Radiat Biol. 1994 Nov;66(5):427-32 14528271 - Oncogene. 2003 Sep 29;22(42):6479-83 16079181 - Mol Biol Cell. 2005 Oct;16(10):4623-35 15383798 - Ann Surg. 2004 Oct;240(4):711-7; discussion 717-8 17380162 - Nat Rev Mol Cell Biol. 2007 Apr;8(4):284-95 12878854 - Cancer Biol Ther. 2003 May-Jun;2(3):233-5 15078986 - Mol Cancer Ther. 2004 Apr;3(4):425-35 1511188 - Crit Rev Eukaryot Gene Expr. 1992;2(3):251-63 11677656 - Semin Radiat Oncol. 2001 Oct;11(4):316-27 1679088 - Int J Radiat Biol. 1991 Sep;60(3):483-96 15069698 - Int J Cancer. 2004 Jun 10;110(2):301-8 12175305 - Radiat Res. 2002 Sep;158(3):251-91 14612513 - Cancer Res. 2003 Nov 1;63(21):7190-6 15850925 - Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):223-9 7973635 - Science. 1994 Nov 4;266(5186):807-10 15234026 - Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):928-42 8917731 - Experientia. 1996 Oct 31;52(10-11):1001-7 14963330 - Science. 2004 Feb 13;303(5660):1010-4 11062378 - Mol Urol. 2000 Fall;4(3):225-9;discussion 231 17121856 - J Biol Chem. 2007 Feb 16;282(7):4765-71 4674589 - Radiat Res. 1972 Nov;52(2):373-94 12892709 - Cancer Cell. 2003 Jul;4(1):13-8 12907619 - Cancer Res. 2003 Aug 1;63(15):4460-71 12972501 - J Cell Sci. 2003 Oct 15;116(Pt 20):4077-85 18765532 - Clin Cancer Res. 2008 Sep 1;14(17):5410-5 1933891 - Cancer Res. 1991 Dec 1;51(23 Pt 1):6304-11 9822382 - Science. 1998 Nov 20;282(5393):1497-501 15077116 - Nat Cell Biol. 2004 May;6(5):443-50 11547717 - N Engl J Med. 2001 Aug 30;345(9):638-46 |
References_xml | |
SSID | ssj0006067 |
Score | 2.2235193 |
Snippet | Agents that inhibit histone deacetylases (HDAC inhibitors) have been shown to enhance radiation response. The aim of this study was to evaluate the effects of... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 689 |
SubjectTerms | Animals bcl-2-Associated X Protein - drug effects bcl-2-Associated X Protein - metabolism Cell Cycle - radiation effects Cell Division - drug effects Cell Division - radiation effects Cell Line, Tumor Colorectal Neoplasms - pathology Colorectal Neoplasms - radiotherapy Cytochromes c - metabolism Cytochromes c - radiation effects Flow Cytometry Genotype Histone Deacetylase Inhibitors - pharmacology Humans Membrane Potentials - radiation effects Mice Mitochondria - metabolism Mitochondria - radiation effects Mitochondrial Membranes - physiology Mitochondrial Membranes - radiation effects Radiation-Sensitizing Agents - pharmacology T-Lymphocytes - immunology T-Lymphocytes - radiation effects Tumor Suppressor Protein p53 - deficiency Tumor Suppressor Protein p53 - genetics Tumor Suppressor Protein p53 - metabolism Valproic Acid - pharmacology |
Title | HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells |
URI | https://www.ncbi.nlm.nih.gov/pubmed/20025549 |
Volume | 24 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NS8MwFA-bgngRv78lB_GyFbs1a9Oj1MkuytAJehDJJxZ0G1t38L_3pUm7biLowUspSRtCfj9e3nu8D4TOWzSiXMbCE4AwGCg68KhSzJM6lkx3QsYCk43ce4junuh1l3RrtaJD1XzsX5GGMcDaZM7-Ae1yURiAd8AcnoA6PH-Fe-_6Kmmkw7eUp5k1xWF1EJOmLqtIczzBDJ-ZQKwxnFvRBDdrTJhMR1MTz5653Ewbcv4OL8JwY9IwXv5pVZ1N7DhPXR6XDb_JVxq_VZ3lpeaeuGyQp5lW7tKsBAb3WZaVPv57JkFSFcJ6-VOXgtZ4dn7ewnMRV6JAlJO2HbgiaWdBHNuUake7qmwNba-hbzLfp6ZkquATV300bC98B_CMP3Kw27kBRX4xu1SCu5iqozooVEbnTm7L6x4swMgVb4WdXC7sw5Sadv8umS25-jLYRBvO7sBXljBbqKaG22jt1kVWbKOLvsXrs4kH85S8aRNf4P68uvnnDnoxBMMlwZq4oBc29GpiRy68QC78nVx4pHFOLmzJhXNy7aLHm-4g6XmuR4cnCA0yT7cYg3uKKc2JoNyXIO9jSpT0JTVp26HQhIPSz1SkAxALlGgZStNII4pbgrD2HloZjobqAOFASlD-eSA7vEV0wGNf-pwr0N852MhUHKJ9e4KvY1uI5bU426MfZ47R-px5J2hVA-HVKapP5ewsh_ELh6V0zg |
link.rule.ids | 782 |
linkProvider | EBSCOhost |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HDAC+inhibitor%2C+valproic+acid%2C+induces+p53-dependent+radiosensitization+of+colon+cancer+cells&rft.jtitle=Cancer+biotherapy+%26+radiopharmaceuticals&rft.au=Chen%2C+Xufeng&rft.au=Wong%2C+Patty&rft.au=Radany%2C+Eric&rft.au=Wong%2C+Jeffrey+Y+C&rft.date=2009-12-01&rft.eissn=1557-8852&rft.volume=24&rft.issue=6&rft.spage=689&rft_id=info:doi/10.1089%2Fcbr.2009.0629&rft_id=info%3Apmid%2F20025549&rft_id=info%3Apmid%2F20025549&rft.externalDocID=20025549 |